

# Accepted Manuscript

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection

Paul Kwo, Edward Gane, Cheng-Yuan Peng, Brian Pearlman, John M. Vierling, Lawrence Serfaty, Maria Buti, Stephen Shafran, Paul Stryszak, Li Lin, Jacqueline Gress, Stuart Black, Frank J. Dutko, Michael Robertson, Janice Wahl, Lisa Lupinacci, Eliav Barr, Barbara Haber

PII: S0016-5085(16)35170-8  
DOI: [10.1053/j.gastro.2016.09.045](https://doi.org/10.1053/j.gastro.2016.09.045)  
Reference: YGAST 60739

To appear in: *Gastroenterology*  
Accepted Date: 16 September 2016

Please cite this article as: Kwo P, Gane E, Peng C-Y, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B, Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection, *Gastroenterology* (2016), doi: 10.1053/j.gastro.2016.09.045.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients with Chronic Hepatitis C Infection**

Paul Kwo,<sup>1</sup> Edward Gane,<sup>2</sup> Cheng-Yuan Peng,<sup>3</sup> Brian Pearlman,<sup>4</sup> John M. Vierling,<sup>5</sup> Lawrence Serfaty,<sup>6</sup> Maria Buti,<sup>7</sup> Stephen Shafran,<sup>8</sup> Paul Stryszak,<sup>9</sup> Li Lin,<sup>9</sup> Jacqueline Gress,<sup>9</sup> Stuart Black,<sup>9</sup> Frank J. Dutko,<sup>9</sup> Michael Robertson,<sup>9</sup> Janice Wahl,<sup>9</sup> Lisa Lupinacci,<sup>9</sup> Eliav Barr,<sup>9</sup> and Barbara Haber<sup>9</sup>

<sup>1</sup>Indiana University, Indianapolis, Indiana; <sup>2</sup>Auckland Clinical Studies, Grafton, Auckland, New Zealand; <sup>3</sup>School of Medicine, China Medical University, Taichung, Taiwan; <sup>4</sup>Center for Hepatitis C, Atlanta Medical Center, Atlanta, Georgia; <sup>5</sup>Baylor College of Medicine, Baylor-St. Luke's Medical Center, Houston, Texas; <sup>6</sup>Service d'Hépatologie, Hôpital Saint-Antoine, APHP, UPMC Paris 6, Paris, France; <sup>7</sup>Hospital Universitari Vall d'Hebron, and Ciberehd del Instituto Carlos III, Barcelona, Spain; <sup>8</sup>University of Alberta, Edmonton, Alberta, Canada; <sup>9</sup>Merck & Co., Inc., Kenilworth, New Jersey

**Reprint requests**

Address reprint requests to: Paul Kwo, MD Gastroenterology/Hepatology Division, Indiana University School of Medicine, 975 W. Walnut, IB 327, Indianapolis, IN 46202-5121  
(pkwo@iu.edu)

**Short Title:** EBR/GZR ± RBV in treatment-experienced HCV Patients

Download English Version:

<https://daneshyari.com/en/article/5658741>

Download Persian Version:

<https://daneshyari.com/article/5658741>

[Daneshyari.com](https://daneshyari.com)